Research Articles - Macular Degeneration
StemCells, Inc. , which launched a Phase I/II clinical trial for its dry age-related macular degeneration (AMD) therapy in October 2012, has begun administering the highest dose of its treatment to patients in the study. The fifth patient in the trial has received a transplant of one million of the company’s human neural stem cells known as HuCNS-SC ® .
Researchers from the University of Wisconsin School of Medicine and Public Health have determined that people taking commonly prescribed blood-pressure medications — including drugs that open and relax blood vessels and regulate heart rhythm — appear to be at increased risk for age-related macular degeneration (AMD). The findings are based on an analysis of data from a long-term study of approximately 5,000 residents of Beaver Dam, Wisconsin, funded by the National Eye Institute.
Researchers have determined that a common blood test for assessing cardiovascular disease risk can also indicate risk for age-related macular degeneration (AMD). They found that people with high levels of high-sensitivity C-reactive protein (hsCRP) — a biomarker for inflammation related to heart disease, cancer and other conditions — have a 49 percent greater risk of all forms of AMD compared to those with low levels of hsCRP. High levels of hsCRP are also associated with an 84 percent increased
A groundbreaking treatment for retinal degenerations is poised to become the second-ever stem cell therapy to move into a Phase I/II clinical trial. The company StemCells, Inc. (SCI), has received authorization from the FDA to launch a clinical trial of its neural stem cell treatment for people with the dry age-related macular degeneration (AMD).
SCI’s announcement came 10 days after Advanced Cell Technology (ACT), which
- An international team of researchers was able to temporarily restore some vision in blind mice by treating their retinas with a chemical called acrylamide-azobenzene-quaternary ammonium (AAQ). While the research is still at an early stage, AAQ, or a derivative, might be used someday to restore vision in people who are blind from advanced retinal degenerations, such as retinitis pigmentosa (RP) or age-related macular degeneration.
- To help people with retinal degenerative diseases better understand issues related to cataracts and their removal, Foundation-funded clinicians Richard Weleber, M.D., of the Casey Eye Institute, Oregon Health & Science University, and Jacque Duncan, M.D., of the University of California, San Francisco, provide the following answers to commonly asked questions:
Promising reports from several human studies for emerging retinal disease treatments highlighted the 2012 meeting of the Association for Research in Vision and Ophthalmology (ARVO) held in Ft. Lauderdale, Florida, May 6-10. As the world’s largest eye-research event, the meeting convened more than 12,000 doctors, scientists and industry professionals, who attended thousands of presentations on the latest
An emerging therapy to slow the progression of geographic atrophy (GA), the advanced form of dry age-related macular degeneration (AMD), has performed encouragingly in an 18-month, Phase II clinical trial involving 143 participants. The results provide some optimism for preserving vision from a leading cause of blindness in people over 50 in developed countries.